ClinicalTrials.Veeva

Menu

Is Mitral Velocity Time-integral a Marker of Preload-responsiveness in Patients With Acute Circulatory Failure?

A

Avicenna Military Hospital

Status

Completed

Conditions

Preload-responsiveness

Treatments

Diagnostic Test: Echocardiography

Study type

Observational

Funder types

Other

Identifiers

NCT05538637
Mitral VTI ICU-AMH

Details and patient eligibility

About

The aim of this is to assess the reliability of the variability of the mitral velocity time-integral with passive leg raising to predict the fluid responsiveness in patients with acute circulatory failure in intensive care.

Full description

Adult patients with acute circulatory failure will be included in the study. An initial echocardiography is performed in patients placed in a semi-recumbent position. On the apical views (4 and 5-chamber views), the left ventricular outflow tract velocity time integral (LVOT-VTI) and mitral valve (MV-VTI) velocity time integral are measured (baseline values). Then a passive leg raise test is performed and the parameters (LVOT-VTI and MV-VTI) are measured again. Preload-responsiveness is defined by an increase in LVOT-VTI of at least 10%. In preload-responsive patients, a fluid loading with 500 ml of 0.9% saline administered over 15 minutes is performed. Immediately after fluid therapy, the same parameters are recorded during a third echocardiography. An increase of 10% or more of LVOT-VTI , compared with baseline, defines fluid responsiveness. Patients are monitored using the standard of care practices. Hemodynamic assessment includes repetitive echocardiographic examinations if needed. In patients with shock, invasive blood pressure is monitored with an arterial catheter.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Acute circulatory failure.

Exclusion Criteria:

  • Recent surgery (<5 days)
  • Suspected or confirmed intra-abdominal hypertension.
  • Intracranial hypertension.
  • Severe mitral valve disease: Severe mitral insufficiency or severe mitral stenosis
  • Acute cor pulmonale
  • Atrial fibrillation
  • Low echogenicity

Trial contacts and locations

1

Loading...

Central trial contact

Younes Aissaoui, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems